J. Dey, A. Mukherjee, S. Dey, Abhishek Pramanik, S. Giri, Mukut Pratap
求助PDF
{"title":"A systematic review on the efficacies and therapeutic interventions of homoeopathic medicines in combating viral disorders with implications in the currently undergoing homoeopathic treatment efforts of SARS-CoV-2 infection (COVID-19)","authors":"J. Dey, A. Mukherjee, S. Dey, Abhishek Pramanik, S. Giri, Mukut Pratap","doi":"10.51910/IJHDR.V19I3.1033","DOIUrl":null,"url":null,"abstract":"The prevalence of Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) has undergone a historic transition from December 2019 to June 2020 Under the current circumstances, SARS-CoV-2 has become a key problem for the public health and economic steadiness of the global fraternity Based on ample evidences from the global epidemiology of SARS-CoV-2 and MERS-CoV (Middle East Respiratory Syndrome-Corona virus) scientists and physicians strappingly consider these viruses share structural and functional similarities of selected biologically active enzymes namely, 3CLpro, PLpro and RdRp Ultra-diluted homoeopathic medicine has the legacy to combat infectious as well as viral diseases since last two centuries Thus, a systematic review on existing antiviral homoeopathic therapies was done in the current study and the need of appropriate clinical validation with proper in vitro as well as in vivo studies prior to make clinical endorsements in treating COVID-19 patients with homoeopathic medicines has been explained A brief summary of the currently undergoing or recently completed homoeopathic treatments of COVID-19 has also been provided to attract many more similar homoeopathic treatment attempts to combat COVID-19 © International Journal of High Dilution Research","PeriodicalId":53565,"journal":{"name":"International Journal of High Dilution Research","volume":"20 1","pages":"27-39"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of High Dilution Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51910/IJHDR.V19I3.1033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
引用
批量引用
顺势疗法药物治疗病毒性疾病的疗效和干预措施及其对当前顺势疗法治疗SARS-CoV-2感染(COVID-19)的影响
从2019年12月到2020年6月,严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2)的流行经历了历史性转变。基于SARS-CoV-2和MERS-CoV(中东呼吸综合征冠状病毒)全球流行病学的大量证据,科学家和医生认为这些病毒在结构和功能上具有相似性,即3CLpro,自过去两个世纪以来,超稀释顺势疗法药物在对抗传染病和病毒性疾病方面具有悠久的历史。本研究对现有的抗病毒顺势疗法进行了系统回顾,并解释了在使用顺势疗法药物治疗COVID-19患者的临床认可之前,需要通过适当的体外和体内研究进行适当的临床验证。还简要总结了目前正在进行或最近完成的COVID-19顺势疗法治疗,以吸引更多类似的顺势疗法治疗尝试COVID-19©国际高稀释研究杂志
本文章由计算机程序翻译,如有差异,请以英文原文为准。